

|   |  |
|---|--|
| Clerk of the House of Representatives<br>Legislative Resource Center<br>B-106 Cannon Building<br>Washington, DC 20515 | Secretary of the Senate<br>Office of Public Records<br>232 Hart Building<br>Washington, DC 20510 |
|---|--|

SECRETARY OF  
02 APR 17

# LOBBYING REPORT

Lobbying Disclosure Act (Section 5) - All Filers Are Required To Complete This Page

|  |                                  |   |                           |
|--|----------------------------------|---|---------------------------|
| 1. Registrant Name<br><b>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</b>   |                                  |   |                           |
| 2. Address <input type="checkbox"/> Check is different than previously reported<br><b>701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20004</b> |                                  |   |                           |
| 3. Principal Place of Business (if different from line 2)<br>City: _____ State/Zip (or Country) _____  |                                  |   |                           |
| 4. Contact Name<br><b>Peter M. Kazon</b>   | Telephone<br><b>202-434-7300</b> | E-mail (optional)<br><b>pmkazon@mintz.com</b> | 5. Senate<br><b>1923-</b> |
| 7. Client Name <input type="checkbox"/> Self<br><b>American Clinical Laboratory Association</b>  |                                  |   | 6. House<br><b>30533</b>  |

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30)  **OR** Year End (July 1-D

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

|   |   |
|---|---|
| <p align="center"><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> \$ _____<br/>Expenses (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p> | <p align="center"><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for the period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> \$ _____<br/>Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description.</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p> |
|---|---|

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Mintz, Levin, Cohn, Ferris, et al. Client Name American Clinical Lab. As

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the regi in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide inform: requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

**Congressional Issues: Medicare reimbursement for clinical laboratories.**

**Implementation of provisions of Balanced Budget Act of 1997 applicable to laboratories.**

**H.R. 1798/S. 1066, Medicare Patient Access to Preventive and Diagnostic Tests Act**

**Labor - HHS appropriations bills**

**Executive Branch Actions: Correspondence with Administrator, Centers for Medicare and Medicaid Services formerly Health Care Financing Administration) re various issues affecting clinical laboratories; corresponde Administrator, Food and Drug Administration (FDA) re various issues affecting clinical laboratories; correspo Department of Transportation Research and Special Projects Administration re packaging of laboratory specii correspondence with Centers for Disease Control and Prevention (CDC) re same.**

17. House(s) of Congress and Federal agencies contacted  Check if None

**U.S. House of Representatives**

**U.S. Senate**

**U.S. Department of Health and Human Services**

18. Name of each individual who acted as a lobbyist in this issue area

| Name                      | Covered Official Position (if applicable) |
|---------------------------|---|
| <b>Peter M. Kazon</b>     |   |
| <b>Erin Lewis Darling</b> |   |

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Mintz, Levin, Cohn, Ferris, et al. Client Name American Clinical Lab. A

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the reg in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide inform requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

**Congressional Issues: Medicare reimbursement for clinical laboratories.  
Implementation of provisions of Balanced Budget Act of 1997 applicable to laboratories.  
H.R. 1798/S. 1066, Medicare Patient Access to Preventive and Diagnostic Tests Act  
Labor - HHS appropriations bills**

**Executive Branch Actions: Correspondence with Administrator, Centers for Medicare and Medicaid Services formerly Health Care Financing Administration) re various issues affecting clinical laboratories; corresponde Administrator, Food and Drug Administration (FDA) re various issues affecting clinical laboratories; correspo Department of Transportation Research and Special Projects Administration re packaging of laboratory speci correspondence with Centers for Disease Control and Prevention (CDC) re same.**

17. House(s) of Congress and Federal agencies contacted  Check if None

**U.S. House of Representatives  
U.S. Senate  
U.S. Department of Health and Human Services**

18. Name of each individual who acted as a lobbyist in this issue area

| Name                      | Covered Official Position (if applicable) |
|---------------------------|---|
| <b>Peter M. Kazon</b>     |   |
| <b>Erin Lewis Darling</b> |   |

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Mintz, Levin, Cohn, Ferris, et al. Client Name American Clinical Lab. A

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the reg: in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide inform requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

**Congressional Issues: Medicare reimbursement for clinical laboratories.  
Implementation of provisions of Balanced Budget Act of 1997 applicable to laboratories.  
H.R. 1798/S. 1066, Medicare Patient Access to Preventive and Diagnostic Tests Act  
Labor - HHS appropriations bills**

**Executive Branch Actions: Correspondence with Administrator, Centers for Medicare and Medicaid Services formerly Health Care Financing Administration) re various issues affecting clinical laboratories; corresponde Administrator, Food and Drug Administration (FDA) re various issues affecting clinical laboratories; correspo Department of Transportation Research and Special Projects Administration re packaging of laboratory specifi correspondence with Centers for Disease Control and Prevention (CDC) re same.**


17. House(s) of Congress and Federal agencies contacted  Check if None

**U.S. House of Representatives  
U.S. Senate  
U.S. Department of Health and Human Services**

18. Name of each individual who acted as a lobbyist in this issue area

| Name                      | Covered Official Position (if applicable) |
|---------------------------|---|
| <b>Peter M. Kazon</b>     |   |
| <b>Erin Lewis Darling</b> |   |

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature   
Printed Name and Title Peter M. Kazon, Member

